JSPR
Jasper Therapeutics, Inc.
$0.4927
+2.43%
$13.5M
No data for this timeframe.
Vol
Market Cap$13.5M
Cap SizeNano Cap
Analyst ConsensusBuy (64%)
Inst. Holders6 funds
Inst. Value$7.0M
Inst. Activity2 buys / 2 sells
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001788028·Prev Close $0.4810
Recent Activity
Feb 6, 2026
Insider
Mahal Jeetinder Singh sold 500,000 shares
CEO and President @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
1,969,785 shares ($3.6M)
Inst.
VANGUARD GROUP INC — ADD
1,326,512 shares ($2.4M)
Jun 3, 2026
short_volume
Short Volume: JSPR — 62.0% short (0.6M / 1.0M)
Short: 646,187 | Exempt: 120,382 | TRF Vol: 1,042,141 | Short Ratio: 62.0% | Off-exchange volume (da
Jun 1, 2026
Press
Jasper Therapeutics announced a comprehensive review of strategic alternatives, including a potential sale, licensing, m
Impact 8/10
Price Targets
$7.50
+1422.2% upside
Strong Buy
Current $0.4927
Low $1.50
Median $6.00
High $20.00
5 analysts
$1.50
$20.00
Analyst Ratings
3Strong Buy
6Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | TD Cowen | DOWNGRADE | Buy → Hold |
| May 15, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| Apr 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.55 | $-0.55 — $-0.55 | 68% YoY | 1 |
| Next Q | $-0.56 | $-0.56 — $-0.56 | 55% YoY | 1 |
| Current FY | $-2.44 | $-3.29 — $-1.34 | 45% YoY | 4 |
| Next FY | $-1.85 ▼ -10.8% | $-2.56 — $-1.14 | 24% YoY | 2 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $3.6M | DOUBLED |
| VANGUARD GROUP INC | $2.4M | ADD |
| BANK OF AMERICA CORP | $536.2K | — |
| RENAISSANCE TECHNOLOGIES LLC | $415.7K | DOUBLED |
| FMR LLC | $21.9K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 6, 2026 | Mahal Jeetinder | A | $0.00 |
6 institutional holders with $7.0M total value (3,829,756 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 1,969,785 | $3.6M | 51.4% | DOUBLED +149.4% |
| 2 | VANGUARD GROUP INC | 1,326,512 | $2.4M | 34.6% | ADD +28.4% |
| 3 | BANK OF AMERICA CORP /DE/ | 293,027 | $536.2K | 7.7% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 227,183 | $415.7K | 5.9% | DOUBLED +1904.8% |
| 5 | FMR LLC | 11,949 | $21.9K | 0.3% | TRIM -36.9% |
| 6 | WELLS FARGO & COMPANY/MN | 1,300 | $2.4K | 0.0% | TRIM -43.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 789,960 | 1,969,785 | +149.4% | $3.6M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 1,032,842 | 1,326,512 | +28.4% | $2.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 2,300 | 1,300 | -43.5% | $2.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 40,427 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 624,597 | 1,032,842 | +65.4% | $2.5M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,400 | 208,500 | +1904.8% | $496.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 40,427 | — | $96.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 416,275 | 39,354 | -90.5% | $93.7K | 2025-Q3 |
| FMR LLC | TRIM | 18,856 | 11,899 | -36.9% | $28.3K | 2025-Q3 |
| FMR LLC | ADD | 15,014 | 18,856 | +25.6% | $104.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 10,400 | — | $57.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 6,110 | 2,479 | -59.4% | $13.8K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 26,648 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 164,315 | 534,636 | +225.4% | $2.3M | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 388,523 | 15,014 | -96.1% | $64.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 147,064 | 437,910 | +197.8% | $9.4M | 2024-Q4 |
| UBS Group AG | DOUBLED | 5,317 | 164,315 | +2990.4% | $3.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 3,587 | 7,415 | +106.7% | $158.5K | 2024-Q4 |
| MORGAN STANLEY | ADD | 309,419 | 565,722 | +82.8% | $10.6M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 32,407 | — | $609.6K | 2024-Q3 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Mahal Jeetinder Singh | CEO and President | A | 500,000 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Current analyst consensus: Buy (64% buy). Based on 14 analysts: 3 strong buy, 6 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.50 mean target
+1422.2% upside
Strong Buy (2.29)
$1.50 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4927 |
| Target Low | $1.50 |
| Target Mean | $7.50 |
| Target Median | $6.00 |
| Target High | $20.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (2.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.55 | $-0.55 | $-0.55 | 68.4% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.56 | $-0.56 | $-0.56 | 55.3% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-2.44 | $-3.29 | $-1.34 | 44.5% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-1.85 | $-2.56 | $-1.14 | 24.2% | -10.8% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.550 | |
| 7d ago | $-0.550 | |
| 30d ago | $-0.550 | |
| 60d ago | $-0.550 | |
| 90d ago | $-0.693 | +0.143 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| May 15, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Apr 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| May 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| Apr 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| Mar 1, 2026 | 3 | 8 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 3 | 8 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 3 | 8 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: JSPR — 62.0% short (0.6M / 1.0M)
Short: 646,187 | Exempt: 120,382 | TRF Vol: 1,042,141 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: JSPR — 61.3% short (1.2M / 1.9M)
Short: 1,190,730 | Exempt: 192,021 | TRF Vol: 1,940,920 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
activist
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
<p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biote
Jun 1, 2026
short_volume
Short Volume: JSPR — 55.1% short (0.9M / 1.6M)
Short: 882,980 | Exempt: 75,520 | TRF Vol: 1,602,749 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 25, 2026
Clinical Trial
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: Briquilimab (Phase 2)
Trial: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Briquilimab (Phase 2)
Trial: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored
May 13, 2026
earnings_calendar
JSPR Q1 2026 Earnings Before Market Open — 2026-05-13
May 11, 2026
earnings_calendar
JSPR Q1 2026 Earnings Before Market Open — 2026-05-11
Apr 9, 2026
short_volume
Short Volume: JSPR — 68.3% short (0.5M / 0.7M)
Short: 458,602 | Exempt: 0 | TRF Vol: 671,080 | Short Ratio: 68.3% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: JSPR — 62.8% short (0.4M / 0.7M)
Short: 415,944 | Exempt: 35,561 | TRF Vol: 662,292 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
<p align="justify">REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biot
Mar 2, 2026
earnings_calendar
JSPR Q4 2025 Earnings After Market Close — 2026-03-02
Feb 25, 2026
earnings_calendar
JSPR Q4 2025 Earnings After Market Close — 2026-02-25